| Date | Title | Description |
| 07.05.2024 | Memo Therapeutics raises additional CHF20 million |
Schlieren-based Memo Therapeutics is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat B... |
| 06.12.2023 | Leadership changes with some promotions | |
| 02.11.2023 | Memo Therapeutics Raises CHF 25 Million Series C Financing | |
| 02.11.2023 | Memo Therapeutics Raises CHF 25M in Series C Financing | Memo Therapeutics, a Schlieren / Zurich, Switzerland-based late-stage biotech company, raised CHF 25M in Series C funding.
The round was led by Pureos Bioventures, with participation from xisting investors Swisscanto, Vesalius Biocapital, A... |
| 03.05.2023 | Memo Therapeutics kicks off phase II/III trials after receiving FDA Fast Track Designation | |
| 13.04.2023 | Preventing the Next Pandemic: The Innovative Solutions Leading the Way | The COVID-19 pandemic created an unprecedented health and societal crisis for many of us across the world. Its death toll estimates place it among history’s deadliest plagues. Despite having much more advanced economic, healthcare, and tech... |
| 25.01.2023 | Positive results for new drug targeting kidney transplant recipients | |
| 01.11.2022 | Ono Pharmaceutical relies on Memo Therapeutics for antibody discovery | |
| 01.06.2022 | Memo Therapeutics enters clinical stage with an antibody against BK virus infection | |
| 16.02.2022 | Memo Therapeutics raises CHF 23 million | |
| 16.02.2022 | Memo Therapeutics Raises CHF23M Extension; Closes CHF37M Series B Financing | Memo Therapeutics AG, a Schlieren, Switzerland-based innovator in the field of antibody discovery and development, closed a Series B financing round of CHF37m after securing an additional CHF23m.
The round was led by Swisscanto Invest and i... |
| 16.02.2022 | Memo Therapeutics raises CHF 37 million in an oversubscribed Series B fundraising round | Memo Therapeutics raises CHF 37 million in an oversubscribed Series B fundraising round 16.02.2022 09:27, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
Memo Therapeutics AG (“MTx”), an innovator in the field of antibo... |
| 15.12.2021 | Memo Therapeutics gets CHF 10.5 million from the Swiss government to clinically develop their antibody against COVID-19 | Memo Therapeutics gets CHF 10.5 million from the Swiss government to clinically develop their antibody against COVID-19 15.12.2021 20:35, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
Memo Therapeutics, an innovator in... |
| 13.12.2021 | Federal government signs four contracts for the development of COVID-19 medicines | |
| 20.07.2021 | Startups welcome legendary board members aboard | DiNAQor – three prominent cardiovascular industry and Academic Experts
Louis G. Lange, Steven Zelenkofske, and Silke Rickert-Sperling, some of the most renowned cardiovascular industry and academic experts are joining the board of directors... |
| 17.05.2021 | Memo Therapeutics antibodies show efficacy against Covid-19 variants | Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo Therapeutics can discover novel antibodies at high speed, efficiency and sensitivity derived ... |
| 17.05.2021 | Memo Therapeutics antibodies show efficacy against Covid-19 variants | |
| 09.11.2020 | Switzerland's Memo Therapeutics lands €13M | Biotech startup Memo Therapeutics has raised 14 million Swiss francs (around €13 million) in a led by Swisscanto Invest. The funds will be used in part to advance Memo's antibody candidate for COVID-19 through to Phase II clinical studies.
... |
| 06.11.2020 | Memo Therapeutics raises CHF14 Million for Covid antibody development | Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis. Its antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enab... |
| 06.11.2020 | Memo Therapeutics raises CHF14 Million for Covid antibody development | |
| 06.11.2020 | Memo Therapeutics Raises CHF 14M in Series B Financing Round | Memo Therapeutics AG, a Schliren, Switzerland-based antibody discovery and immune repertoire analysis company, raised CHF 14m in Series B financing.
The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInve... |
| 06.11.2020 | Memo Therapeutics receives CHF14M in Series B financing round for COVID-19 antibody development | Memo Therapeutics receives CHF14M in Series B financing round for COVID-19 antibody development 06.11.2020 11:10, Jonatan Masseus linkedIn facebook twitter instagram youtube -->
Schlieren-based Memo Therapeutics is on the hunt for clinic... |
| 06.11.2020 | Memo Therapeutics AG : Raises CHF 14 Million in a Series B Financing Round | Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised CHF 14 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kanton... |
| 06.11.2020 | Swiss biotech Memo Therapeutics lands €13.9 million to advance its COVID-19 antibody treatment | Swiss company Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised around €13.9 million in Series B financing. The round was led by Swisscanto Inve... |
| 04.06.2020 | Memo Therapeutics identifies SARS-CoV-2 neutralizing antibodies | |
| 04.06.2020 | Memo Therapeutics identifies SARS-CoV-2 neutralizing antibodies | Since March, Memo Therapeutics (MTx) has selected the most promising donors from hundreds of Swiss COVID-19 patients. The selection criteria identified patients who had demonstrated a clinical course of COVID-19 indicative of a particularly... |
| 13.05.2020 | Swiss Startups Tackling Corona Virus - COVID-19 | Swiss Startups Tackling Corona Virus - COVID-19 13.05.2020 13:14, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Corona Virus is changing our society, our economy and our lifestyle. Remote working and online collaborati... |
| 28.10.2019 | Memo Therapeutics to receive milestone and royalty payments | |
| 11.09.2019 | One step closer to changing the outcome of renal transplantations | |
| 09.05.2018 | Memo Therapeutics Closes CHF5.0M Series A2 Financing Round | Memo Therapeutics AG, a Basel, Switzerland-based innovator in the field of antibody discovery and human immune repertoire analysis, closed a CHF 5.0m Series A2 financing round.
The round included new investors Schroder Adveq, investiere.ch ... |
| 28.03.2017 | 22 startups selected to pitch at the Swiss Venture Day - reloaded | |
| 23.07.2015 | Memo Therapeutics Closes CHF2.3M Series A Financing | Memo Therapeutics, a Basel/Zurich-based developer of a platform technology for antibody discovery, closed a CHF2.3m Series A financing.
The round by Redalpine and other Swiss investors, including EVA Basel and Zürcher Kantonalbank.
The comp... |
| 22.07.2015 | Memo Therapeutics raises CHF 2.3 million | |
| - | Memo Therapeutics | “Home - Memo Therapeutics AG” |
